Literature DB >> 23231465

Viewpoint: the ENIGMAS trial - when should we treat patients with moderate aortic stenosis?

Alexandru Nicolae Mischie1, Catalina Liliana Andrei, Crina Sinescu.   

Abstract

Aortic stenosis (AS) is the most frequent valvular heart disease encountered in our daily practice. Although there are clear guidelines for severe AS management, cardiologists often have few treatment options for patients with moderate AS; however, there is higher mortality in this patient subgroup versus an age-matched population. The authors reviewed all of the studies on moderate AS, summarized the factors that increase disease progression and discussed an ideal trial design to prospectively evaluate AS progression factors using modern cardiology tools such as strain and magnetic resonance imaging.
© 2012, Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 23231465     DOI: 10.1111/echo.12080

Source DB:  PubMed          Journal:  Echocardiography        ISSN: 0742-2822            Impact factor:   1.724


  3 in total

1.  Timing of Dynamic NT-proBNP and hs-cTnT Response to Exercise Challenge in Asymptomatic Children with Moderate Aortic Valve Regurgitation or Moderate Aortic Valve Stenosis.

Authors:  Wadi Mawad; Sylvia Abadir; Anne Fournier; Jean-Luc Bigras; Daniel Curnier; Lyes Kadem; Nagib Dahdah
Journal:  Pediatr Cardiol       Date:  2015-06-30       Impact factor: 1.655

Review 2.  Antithrombotic treatment tailoring and risk score evaluation in elderly patients diagnosed with an acute coronary syndrome.

Authors:  Alexandru Nicolae Mischie; Catalina Liliana Andrei; Crina Sinescu; Gani Bajraktari; Eugen Ivan; Georgios Nikolaos Chatziathanasiou; Michele Schiariti
Journal:  J Geriatr Cardiol       Date:  2017-07       Impact factor: 3.327

3.  On Left Ventricle Stroke Work Efficiency in Children with Moderate Aortic Valve Regurgitation or Moderate Aortic Valve Stenosis.

Authors:  M Asaadi; W Mawad; A Djebbari; Z Keshavardz-Motamed; N Dahdah; L Kadem
Journal:  Pediatr Cardiol       Date:  2021-08-06       Impact factor: 1.655

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.